Skip to Content

Eszopiclone Dosage

Medically reviewed by Drugs.com. Last updated on May 15, 2019.

Applies to the following strengths: 1 mg; 2 mg; 3 mg

Usual Adult Dose for:

Usual Geriatric Dose for:

Additional dosage information:

Usual Adult Dose for Insomnia

Initial dose: 1 mg orally once a day immediately before bedtime
Maintenance dose: 1 to 3 mg orally once a day immediately before bedtime
Maximum dose: 3 mg/day

Comments:
-The lowest effective dose should be used.
-Patients should be monitored for cognitive and/or motor impairments, especially if this drug is used repeatedly.
-Patients should be reevaluated if insomnia persists after 7 to 10 days of treatment.

Use: Treatment of insomnia

Usual Geriatric Dose for Insomnia

Initial dose: 1 mg orally once a day immediately before bedtime
Maintenance dose: 1 to 2 mg orally once a day immediately before bedtime
Maximum dose: 2 mg/day

Comments:
-The lowest effective dose should be used.
-Patients should be monitored for cognitive and/or motor impairments, especially if this drug is used repeatedly.
-Patients should be reevaluated if insomnia persists after 7 to 10 days of treatment.

Use: Treatment of insomnia

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

Mild to moderate liver dysfunction: No adjustment recommended; use with caution.
Severe liver dysfunction: Up to 2 mg orally once a day immediately prior to bedtime
-Maximum dose: 2 mg/day

Dose Adjustments

CONCOMITANT USE WITH CENTRAL NERVOUS SYSTEM (CNS) DEPRESSANTS: Dose adjustment may be required; however, no specific guidelines have been suggested. Caution is recommended.

DEBILITATED PATIENTS AND/OR THOSE TAKING POTENT CYP450 3A4 INHIBITORS: Up to 2 mg orally once a day immediately prior to bedtime
-Maximum dose: 2 mg/day

Precautions

CONTRAINDICATIONS:
-Hypersensitivity to the active component or to any of the ingredients
-Patients who have previously experienced an episode of complex sleep behavior with this drug or other prescription insomnia medications

US BOXED WARNINGS:
DEPENDENCE RISK:
-This drug is a federally controlled substance (Schedule IV) because it can be abused or lead to dependence.
-Selling or giving away this drug may harm others and is against the law.
Recommendations:
-This drug should be kept in a safe place to prevent misuse and abuse.
-Patients should tell their healthcare provider if they have ever abused or been dependent on alcohol, prescription medications, or street drugs.

RISK OF SERIOUS INJURIES CAUSED BY SLEEPWALKING:
-Rare but serious injuries, including deaths, have occurred with certain common prescription insomnia medications.
-Complex sleep behaviors (e.g., sleepwalking, sleep driving, other activities) occurred in patients with and without a history of such behaviors, even at the lowest recommended doses, and occurred after one dose; patients usually do not remember the events.
-Reported cases included accidental overdoses, burns, carbon monoxide poisoning, drowning/near drowning, exposure to extreme temperature leading to limb loss, hypothermia, motor vehicle collisions with the patient driving, and self-injuries (e.g., gunshot wounds, apparent suicide attempts).
-Sleep behaviors may occur alone or in combination with alcohol or other central nervous system (CNS) depressants (e.g., anti-anxiety agents, opioids, tranquilizers).
Recommendations:
-Use should be avoided in patients who have experienced an episode of complex sleep behavior with prescription insomnia agents.
-Patients should be advised to discontinue treatment and contact their healthcare provider if a complex sleep behavior occurs.
-Patients should expect decreased mental alertness the day after use even if fully awake.

Safety and efficacy have not been established in pediatric patients.

Consult WARNINGS section for additional precautions.

US Controlled Substance: Schedule IV

Dialysis

Data not available

Other Comments

Administration advice:
-Doses should be administered immediately before bedtime.
-The effects of eszopiclone on sleep onset may be reduced if it is taken with or immediately after a high-fat/heavy meal.

General:
-This drug decreased sleep latency and improved sleep maintenance when administered at bedtime in clinical trials.
-Taking a sedative/hypnotic while still up and about may result in short-term memory impairment, hallucinations, impaired coordination, dizziness, and lightheadedness.
-The risk of next day impairment of driving and other activities that require full alertness is increased following use of 2 mg or 3 mg doses.
-Withdrawal effects may occur if the dose is rapidly reduced or treatment discontinued.

Monitoring:
-NERVOUS SYSTEM: Changes in cognitive function, including complex behaviors
-PSYCHIATRIC: New/worsening depression

Patient advice:
-Patients should be instructed to immediately report "sleep driving," other complex behaviors, and any new/worsening signs/symptoms of depression.
-Inform patients that this drug may cause somnolence and/or transient amnesia, and they should remain in bed and avoid driving or operating machinery for a full 7 to 8 hours after administration of this drug.
-Advise patients to speak to their healthcare provider if they become pregnant, intend to become pregnant, or are breastfeeding.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Related questions

Hide